The new NBE Therapeutics R&D center in Basel
)
Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel
news
Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel
Basel, Switzerland, Thursday, 03.04.2025 – Today NBE Therapeutics (NBE) a wholly owned subsidiary of Boehringer Ingelheim, officially opened its new ADC R&D facility in Basel. This milestone reinforces its commitment to innovation in oncology and strengthens its footprint in Switzerland’s biotech ecosystem. NBE Therapeutics, a Swiss biotech founded in 2012 that became part of Boehringer Ingelheim in 2020, plays a pivotal role in the company’s oncology research strategy. The new facility will serve as a leading research center for advancing antibody-drug conjugates (ADC) research and development, supporting Boehringer Ingelheim’s commitment to developing transformative cancer therapies to improve patients’ lives globally.
